{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:11:18Z","timestamp":1790683878292,"version":"4.1.0"},"reference-count":10,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Predicting the onset of type 1 diabetes mellitus (T1D) in patients treated with immune checkpoint inhibitors (ICI) remains challenging. ICI-induced T1D (ICI-T1D) is a rare but serious complication that leads to complete insulin depletion. While diabetes-associated autoantibodies, such as glutamic acid decarboxylase antibodies (GADA), are typically absent in non-ICI-related fulminant T1D, they are relatively common in ICI-T1D. However, it is unclear whether these autoantibodies are detectable before the development of ICI-T1D. We present the case of a 61-year-old man with diabetes who had strongly positive GADA and preserved insulin secretion prior to initiating ICI therapy. Following treatment with durvalumab, he developed ICI-T1D, characterized by complete insulin depletion. Notably, the onset of ICI-T1D was precisely tracked on a daily basis, facilitating the timely initiation of insulin therapy and preventing diabetic ketoacidosis. Although the cost-effectiveness of pretreatment GADA screening and intensive monitoring remains a concern, early detection of diabetes-associated autoantibodies and vigilant glucose monitoring after ICI administration may help predict ICI-T1D and enable early therapeutic intervention.<\/jats:p>","DOI":"10.1210\/jcemcr\/luae252","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T10:39:56Z","timestamp":1737715196000},"source":"Crossref","is-referenced-by-count":2,"title":["Durvalumab-induced Type 1 Diabetes in a Patient With Pre-existing GADA-positive Diabetes and Preserved Insulin Secretion"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8562-2658","authenticated-orcid":false,"given":"Nobuhiro","family":"Nakatake","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Kameda General Hospital , Chiba 296-0041 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kameda General Hospital , Chiba 296-0041 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kontani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kameda General Hospital , Chiba 296-0041 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"5","key":"2025020513055924000_luae252-B1","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc21-2213","article-title":"Immune checkpoint inhibitors and risk of type 1 diabetes","volume":"45","author":"Chen","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"2025020513055924000_luae252-B2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jdi.12024","article-title":"Report of the committee of the Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes Mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus","volume":"3","author":"Imagawa","year":"2012","journal-title":"J Diabetes Investig"},{"issue":"9","key":"2025020513055924000_luae252-B3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet Med"},{"issue":"2","key":"2025020513055924000_luae252-B4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s13340-020-00459-1","article-title":"Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma","volume":"12","author":"Yamaguchi","year":"2020","journal-title":"Diabetol Int"},{"issue":"1","key":"2025020513055924000_luae252-B5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40425-017-0245-2","article-title":"Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer","volume":"5","author":"Godwin","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"11","key":"2025020513055924000_luae252-B6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review","volume":"66","author":"Gauci","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2025020513055924000_luae252-B7","doi-asserted-by":"crossref","first-page":"101657","DOI":"10.1016\/j.beem.2022.101657","article-title":"Type 1 diabetes related to immune checkpoint inhibitors","volume":"36","author":"Tachibana","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2025020513055924000_luae252-B8","doi-asserted-by":"crossref","first-page":"111799","DOI":"10.1016\/j.diabres.2024.111799","article-title":"High glutamic acid decarboxylase antibody titers may be associated with a decline in \u03b2-cell function over time and future insulin deficiency in latent autoimmune diabetes in adults","volume":"215","author":"Haisa","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2025020513055924000_luae252-B9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3803\/EnM.2021.1282","article-title":"Human leukocyte antigens and biomarkers in type 1 diabetes mellitus induced by immune-checkpoint inhibitors","volume":"37","author":"Inaba","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"3","key":"2025020513055924000_luae252-B10","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.2337\/dc23-1964","article-title":"Routine blood glucose monitoring does not predict onset of immune checkpoint inhibitor\u2013induced type 1 diabetes","volume":"47","author":"Akturk","year":"2024","journal-title":"Diabetes Care"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/2\/luae252\/61617309\/luae252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/2\/luae252\/61617309\/luae252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:08:59Z","timestamp":1738760939000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luae252\/7978319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,20]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luae252","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,1,20]]},"article-number":"luae252"}}